Coherus Oncology, Inc.
CHRS
$1.60
$0.020.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 42.17M | 37.16M | 31.64M | 31.68M | 26.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.17M | 37.16M | 31.64M | 31.68M | 26.39M |
| Cost of Revenue | 13.81M | 12.52M | 11.53M | 9.94M | 8.73M |
| Gross Profit | 28.36M | 24.64M | 20.11M | 21.74M | 17.66M |
| SG&A Expenses | 95.90M | 104.50M | 109.80M | 111.28M | 114.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 218.61M | 215.70M | 214.80M | 208.98M | 215.44M |
| Operating Income | -176.43M | -178.54M | -183.16M | -177.30M | -189.05M |
| Income Before Tax | -183.12M | -182.87M | -185.95M | -195.94M | -216.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -183.12 | -182.87 | -185.95 | -195.94 | -216.58 |
| Earnings from Discontinued Operations | 351.15M | 337.84M | 365.70M | 65.00M | 245.09M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 168.02M | 154.97M | 179.75M | -130.94M | 28.51M |
| EBIT | -176.43M | -178.54M | -183.16M | -177.30M | -189.05M |
| EBITDA | -172.51M | -174.48M | -178.52M | -172.49M | -183.78M |
| EPS Basic | 1.46 | 1.33 | 1.54 | -1.13 | 0.27 |
| Normalized Basic EPS | -0.95 | -0.98 | -1.01 | -0.99 | -1.06 |
| EPS Diluted | 1.46 | 1.33 | 1.54 | -1.13 | 0.27 |
| Normalized Diluted EPS | -0.95 | -0.98 | -1.01 | -0.99 | -1.06 |
| Average Basic Shares Outstanding | 468.53M | 463.58M | 462.56M | 461.31M | 458.20M |
| Average Diluted Shares Outstanding | 468.53M | 463.58M | 462.56M | 461.31M | 458.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |